Mingyang Li

Fingolimod overcomes cisplatin resistance in esophageal squamous cell carcinoma by targeting NUP54 to disrupt homologous recombination repair

Cisplatin resistance is a major obstacle in the treatment of esophageal squamous cell carcinoma (ESCC). To address this challenge, we screened a U.S. Food and Drug Administration (FDA)-approved drug library and identified fingolimod, an immunomodulatory agent, as a potent inhibit...